SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing heightened volatility and intense social media debate after President Trump publicly endorsed the company, an move that community members are interpreting as both a strategic signal of long-term government backing and an attempt to counter recent aggressive short-selling campaigns led by figures like Michael Burry. While bulls view the endorsement and embedded defense contracts as a long-term catalyst, skeptics are actively questioning the ethics of the executive intervention and debating the competitive threat posed by emerging AI rivals.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is capturing market attention as investors weigh its latest financial update, which highlights a strategic transition toward production execution, a 30,000-unit shipment guidance for 2026, and a strengthened $430 million cash position. While the community is actively debating the company's valuation and the timeline for material revenue, bullish sentiment is being driven by perceived deep-seated connections to major AI infrastructure players and an increasing confidence that the firm's photonic interposer technology is poised to address critical industry bottlenecks.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is currently experiencing intense volatility following strong quarterly earnings, with a fierce debate unfolding between investors betting on AI-driven revenue acceleration and skeptics concerned about high valuations and competitive threats from emerging AI models. The community is actively discussing the stock's sharp price swings and divided perspectives on its long-term viability in an evolving SaaS landscape, with many traders keeping a close watch on key support levels as they navigate the broader market's uncertainty.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is seeing massive social media engagement and high-volume price action driven by investor excitement over its "Nvidia-adjacent" foundry partnerships and the potential for its proprietary EO polymer technology to become a standard in high-speed AI data infrastructure. Community sentiment remains polarized, with bulls tracking upcoming industry conferences and technical integration milestones, while bears point to the company's long-term history of pre-revenue status and recurring dilution concerns.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow (NOW) is experiencing significant downward pressure as market sentiment shifts due to concerns over AI integration and increased competition from emerging AI models. While bulls highlight strong fundamental growth and ServiceNow's partnership with Anthropic as long-term tailwinds, the community is currently debating whether this recent price action represents a generational buying opportunity or a structural shift in the software-as-a-service (SaaS) business model.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate whether the stock is a deep-value opportunity or a long-term play against concerns of AI-driven obsolescence. Community members are actively discussing potential short squeezes, management's buyback strategies, and the competitive impact of Anthropic, with many bullish investors holding for the long term despite current volatility.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing intense community debate centered on significant institutional short interest and ongoing frustration over the lack of major strategic acquisition news. Investors are actively discussing the impact of dark pool trading volumes and debating whether to vote against the CEO's proposed compensation package as they watch for potential signs of a short squeeze.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is experiencing intense volatility and heavy volume as traders react to a new multi-million dollar order for its 800G data center transceivers, fueling intense debates between momentum-driven bulls and short-sellers citing valuation concerns. The community is actively tracking the stock's role in the broader AI infrastructure buildout while debating whether this latest contract signals sustainable growth or a temporary rally in an overextended sector.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is capturing significant investor attention as shares experience high volatility ahead of a pivotal corporate update regarding the DENALI clinical trial. The community remains heavily divided, with some investors betting on a potential buyout or institutional accumulation due to the company's substantial cash position, while others express concerns over clinical trial risks and recent insider movements.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors focus on its pivot toward domestic heavy rare earth metallization and magnets to meet defense-sector demand, supported by high-profile board appointments and defense contract news. The community is actively debating the company's long-term potential as a critical U.S. supply chain supplier versus concerns regarding its pre-revenue status and recent volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Recommendation of "Hold" from Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE - Get Free Report) has been assigned an average rating of "Hold" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports...

Satellos Bioscience (NASDAQ:MSLE) Now Covered by Analysts at Leerink Partners

Leerink Partners initiated coverage on shares of Satellos Bioscience in a research report on Monday. They set an "outperform" rating and a $20.00 price target on the stock...

Q2 EPS Estimate for Satellos Bioscience Increased by Analyst

Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) - Stock analysts at HC Wainwright upped their Q2 2026 EPS estimates for shares of Satellos Bioscience in a report issued on Monday, March 30th. HC...

FY2030 Earnings Forecast for MSLE Issued By HC Wainwright

Satellos Bioscience Inc. (NASDAQ:MSLE - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Satellos Bioscience in a research note issued to investors on Monday, March 30th. HC Wainwright analyst A. He expects that the company will earn $0.34 per share...

Satellos Bioscience (NASDAQ:MSLE) Price Target Raised to $11.00

HC Wainwright boosted their price objective on shares of Satellos Bioscience from $1.20 to $11.00 and gave the stock a "buy" rating in a research report on Monday...

Satellos Bioscience (NASDAQ:MSLE) Releases Earnings Results

Satellos Bioscience (NASDAQ:MSLE - Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.36...

Satellos Bioscience (NASDAQ:MSLE) Downgraded to "Strong Sell" Rating by Wall Street Zen

Wall Street Zen downgraded Satellos Bioscience to a "strong sell" rating in a research note on Saturday...

Satellos Bioscience (NASDAQ:MSLE) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Satellos Bioscience in a report on Wednesday. They set an "overweight" rating on the stock...

Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (Satellos or the Company), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today...

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

MSLE
Satellos Bioscience Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest MSLE News

MSLESatellos Bioscience Inc